We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+19.45%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$334M
AUM Growth
+$46.3M
Cap. Flow
+$21.1M
Cap. Flow %
6.32%
Top 10 Hldgs %
61.83%
Holding
47
New
7
Increased
16
Reduced
9
Closed
6

Top Buys

Rank Stock Value
1
ARQT icon
Arcutis Biotherapeutics
ARQT
+$7.26M
2
KPTI icon
Karyopharm Therapeutics
KPTI
+$5.28M
3
TBPH icon
Theravance Biopharma
TBPH
+$4.85M
4
KZR
Kezar Life Sciences
KZR
+$3.62M
5
JNCE
Jounce Therapeutics, Inc. Common Stock
JNCE
+$3.57M

Top Sells

Rank Stock Value
1
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$3.37M
2
WHWK
Whitehawk Therapeutics
WHWK
+$3.23M
3
MRSN
Mersana Therapeutics
MRSN
+$2.7M
4
FENC icon
Fennec Pharmaceuticals
FENC
+$2.61M
5
PRQR icon
ProQR Therapeutics
PRQR
+$2.47M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
THRX
26
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$4.33M 1.3%
488,100
-46,900
-9% -$460K
FOCL
27
EDAP TMS S.A.
FOCL
$199M
$4.23M 1.27%
382,400
+75,687
+25% +$855K
ATXS
28
DELISTED
Astria Therapeutics
ATXS
$4.1M 1.23%
302,000
+40,297
+15% +$545K
LQDA icon
29
Liquidia Corp
LQDA
$6.26B
$3.97M 1.19%
575,200
+15,200
+3% +$104K
FBIO icon
30
Fortress Biotech
FBIO
$93.4M
$3.75M 1.12%
304,907
+168,240
+123% +$2M
PHAT icon
31
Phathom Pharmaceuticals
PHAT
$723M
$3.54M 1.06%
496,000
+78,500
+19% +$690K
CDXS icon
32
Codexis
CDXS
$182M
$3.1M 0.93%
750,000
-207,500
-22% -$1.09M
IOVA icon
33
Iovance Biotherapeutics
IOVA
$3.74B
$2.57M 0.77%
+421,000
New +$2.9M
RLAY icon
34
Relay Therapeutics
RLAY
$4.26B
$2.07M 0.62%
+125,500
New +$2.25M
KZR
35
DELISTED
Kezar Life Sciences
KZR
$1.96M 0.59%
+62,500
New +$3.62M
MLYS icon
36
Mineralys Therapeutics
MLYS
$2.3B
$1.8M 0.54%
+115,000
New +$1.94M
STXS icon
37
Stereotaxis
STXS
$147M
$1.77M 0.53%
867,100
-317,900
-27% -$715K
TRVI icon
38
Trevi Therapeutics
TRVI
$2.56B
$1.55M 0.46%
835,800
+350,800
+72% +$794K
PRQR icon
39
ProQR Therapeutics
PRQR
$327M
$1.39M 0.42%
653,000
-807,000
-55% -$2.47M
NYXH
40
Nyxoah
NYXH
$160M
$430K 0.13%
+57,585
New +$323K
MODD icon
41
Modular Medical
MODD
$29.4M
$266K 0.08%
6,117
-2,050
-25% -$140K
ALLK
42
DELISTED
Allakos
ALLK
– –
-153,500
Closed -$1.29M
BCAB icon
43
BioAtla
BCAB
$5.23M
– –
-5,236
Closed -$2.16M
FENC icon
44
Fennec Pharmaceuticals
FENC
$413M
– –
-272,200
Closed -$2.61M
MRSN
45
DELISTED
Mersana Therapeutics
MRSN
– –
-18,400
Closed -$2.7M
ZNTL icon
46
Zentalis Pharmaceuticals
ZNTL
$367M
– –
-167,500
Closed -$3.37M
WHWK
47
Whitehawk Therapeutics
WHWK
$278M
– –
-252,046
Closed -$3.23M
1
2

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2023 Portfolio in Review

As of Q1 2023, Opaleye Management held 47 positions worth $334M, up 16% from $288M the previous quarter. Its ten largest holdings account for 62% of the portfolio.

Opaleye Management deployed $21.1M of net new capital in Q1 2023, opening 7 new positions and adding to 16 existing holdings. Its largest new stake was Arcutis Biotherapeutics: 502,000 shares worth $5.52M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was ProQR Therapeutics, an estimated $2.47M trimmed.

  • Opaleye Management's largest Q1 2023 buy was Arcutis Biotherapeutics: 502,000 shares worth $5.52M.
  • Opaleye Management added most to Karyopharm Therapeutics in Q1 2023, an estimated $5.28M increase.
  • Opaleye Management's biggest Q1 2023 reduction was ProQR Therapeutics, cutting an estimated $2.47M.
  • Opaleye Management fully exited Zentalis Pharmaceuticals in Q1 2023, selling an estimated $3.37M.
  • Opaleye Management's ten largest holdings make up 62% of its $334M portfolio in Q1 2023.
  • Opaleye Management opened 7 new positions and closed 6 in Q1 2023.
  • Opaleye Management's portfolio value rose 16% quarter-over-quarter to $334M.

Based on Opaleye Management's 13F filing for Q1 2023, filed 15 May 2023.